TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DEXTENZA

DEXAMETHASONE Corticosteroid Hormone Receptor Agonists
Ophthalmology Approved 2018-11-30
4
Indications
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2018-11-30
Routes
OPHTHALMIC
Dosage Forms
INSERT

Companies

Active Ingredient: DEXAMETHASONE

DEXTENZA Approval History

Loading approval history...

What DEXTENZA Treats

3 indications

DEXTENZA is approved for 3 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Ocular Inflammation
  • Ocular Pain
  • Allergic Conjunctivitis
Source: FDA Label

Drugs Similar to DEXTENZA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACULAR
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Allergic Conjunctivitis
ACULAR LS
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Ocular Pain
ALREX
LOTEPREDNOL ETABONATE
1 shared
BAUSCH AND LOMB
Shared indications:
Allergic Conjunctivitis
BEPOTASTINE BESILATE
BEPOTASTINE BESILATE
1 shared
SOMERSET THERAPS LLC
Shared indications:
Allergic Conjunctivitis
BEPREVE
BEPOTASTINE BESILATE
1 shared
BAUSCH AND LOMB INC
Shared indications:
Allergic Conjunctivitis
BROMFENAC SODIUM
BROMFENAC SODIUM
1 shared
Lupin
Shared indications:
Ocular Pain
BROMSITE
BROMFENAC SODIUM
1 shared
Sun Pharma
Shared indications:
Ocular Pain
CARBINOXAMINE MALEATE
CARBINOXAMINE MALEATE
1 shared
MIKART
Shared indications:
Allergic Conjunctivitis
KARBINAL ER
CARBINOXAMINE MALEATE
1 shared
AYTU
Shared indications:
Allergic Conjunctivitis
LOTEPREDNOL ETABONATE
LOTEPREDNOL ETABONATE
1 shared
SENTISS
Shared indications:
Allergic Conjunctivitis
LOTEPREDNOL ETABONATE AND TOBRAMYCIN
LOTEPREDNOL ETABONATE
1 shared
ALEMBIC
Shared indications:
Allergic Conjunctivitis
MAXIDEX
DEXAMETHASONE
1 shared
HARROW EYE
Shared indications:
Allergic Conjunctivitis
PROLENSA
BROMFENAC SODIUM
1 shared
BAUSCH AND LOMB
Shared indications:
Ocular Pain
PROMETHAZINE HYDROCHLORIDE; CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE
1 shared
CHARTWELL RX
Shared indications:
Allergic Conjunctivitis
PROMETHAZINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE
1 shared
COSETTE
Shared indications:
Allergic Conjunctivitis
PROMETHAZINE PLAIN
PROMETHAZINE HYDROCHLORIDE
1 shared
PHARMOBEDIENT
Shared indications:
Allergic Conjunctivitis
PROMETHEGAN
PROMETHAZINE HYDROCHLORIDE
1 shared
COSETTE
Shared indications:
Allergic Conjunctivitis
ZERVIATE
CETIRIZINE HYDROCHLORIDE
1 shared
HARROW EYE
Shared indications:
Allergic Conjunctivitis
ZYLET
LOTEPREDNOL ETABONATE
1 shared
BAUSCH AND LOMB
Shared indications:
Allergic Conjunctivitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEXTENZA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. . The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. . 1.1 Ocular Inflammation and Pain Following Ophthalmic Surgery DEXTENZA is indicated for the treatment of ocular inflammation ...

DEXTENZA Patents & Exclusivity

Latest Patent: Apr 2041
Exclusivity: Apr 2028

Patents (7 active)

US12144889 Expires Apr 26, 2041
US11458041 Expires Nov 16, 2037
US12150896 Expires Oct 7, 2036
US8409606 Expires May 14, 2030
US8563027 Expires Feb 12, 2030

Exclusivity

NPP Until Apr 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.